Year 2022 / Volume 114 / Number 2
Letter
Anal neoplasia and perianal Crohn’s disease: myth or reality?

117-118

DOI: 10.17235/reed.2021.8317/2021

Rodrigo Quera, Paulina Núñez, Luis Contreras, Francisco López, Lilian Flores,

Abstract
The association between inflammatory bowel disease (IBD) and anal canal squamous cell carcinoma (SCC) has a low prevalence and is mainly supported by articles that include a series of cases. We describe the clinical, endoscopic and histological findings of a patient with Crohn’s disease (CD) who developed SCC while undergoing biological therapy with active disease.
Share Button
New comment
Comments
No comments for this article
References
1. Slesser AA, Bhangu A, Bower M, et al. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol 2013;22:230-7. doi: 10.1016/j.suronc.2013.08.002.
DOI: 10.1016/j.suronc.2013.08.002
2. Shah SB, Pickham D, Araya H, et al. Prevalence of anal dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2015;13:1955-61. doi: 10.1016/j.cgh.2015.05.031.
DOI: 10.1016/j.cgh.2015.05.031
3. Ruel J, Ko HM, Roda G, et al. Anal neoplasia in Inflammatory Bowel Disease is associated with HPV and perianal disease. Clin Transl Gastroenterol. 2016 Mar 3;7:e148. doi: 10.1038/ctg.2016.8.
DOI: 10.1038/ctg.2016.8
4. Wisniewski A, Fléjou J, Siproudhis L, et al. Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohns Colitis 2017:11:1011-8. doi: 10.1093/ecco-jcc/jjx035
DOI: 10.1093/ecco-jcc/jjx035
5. Beaugerie L, Carrat F, Nahon S, et al. High risk oh anal rectal cancer in patients with anal and/or perianal Crohn´s disease. Clin Gastroenterol Hepatol 2018:16:892-9. doi: 10.1016/j.cgh.2017.11.041.
DOI: 10.1016/j.cgh.2017.11.041
1. Slesser AA, Bhangu A, Bower M, et al. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol 2013;22:230-7. doi: 10.1016/j.suronc.2013.08.002.
DOI: 10.1016/j.suronc.2013.08.002
2. Shah SB, Pickham D, Araya H, et al. Prevalence of anal dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2015;13:1955-61. doi: 10.1016/j.cgh.2015.05.031.
DOI: 10.1016/j.cgh.2015.05.031
3. Ruel J, Ko HM, Roda G, et al. Anal neoplasia in Inflammatory Bowel Disease is associated with HPV and perianal disease. Clin Transl Gastroenterol. 2016 Mar 3;7:e148. doi: 10.1038/ctg.2016.8.
DOI: 10.1038/ctg.2016.8
4. Wisniewski A, Fléjou J, Siproudhis L, et al. Anal neoplasia in Inflammatory Bowel Disease: Classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohns Colitis 2017:11:1011-8. doi: 10.1093/ecco-jcc/jjx035
DOI: 10.1093/ecco-jcc/jjx035
5. Beaugerie L, Carrat F, Nahon S, et al. High risk oh anal rectal cancer in patients with anal and/or perianal Crohn´s disease. Clin Gastroenterol Hepatol 2018:16:892-9. doi: 10.1016/j.cgh.2017.11.041.
DOI: 10.1016/j.cgh.2017.11.041
Related articles

Original

Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life

DOI: 10.17235/reed.2023.9935/2023

Original

Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2023.9808/2023

Original

FiLaC® procedure for highly selected anal fistula patients: indications, safety and efficacy from an observational study at a tertiary referral center

DOI: 10.17235/reed.2023.9644/2023

Letter

Plasma levels of intestinal fatty-acid binding protein (I-FABP), abdominal distension and hydrogen concentration after lactitol small intestinal bacterial overgrowth (SIBO) test

DOI: 10.17235/reed.2023.9578/2023

Original

Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis

DOI: 10.17235/reed.2023.9537/2023

Original

Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease

DOI: 10.17235/reed.2023.9536/2023

Letter

Duodenal stenosis surgical treatment in Crohn’s disease

DOI: 10.17235/reed.2023.9521/2023

Original

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

DOI: 10.17235/reed.2023.9491/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Editorial

Relevance of patient-reported outcome measures (PROM) and patient-reported experience measures (PREM) to assess disease status and quality of care in patients with inflammatory bowel disease

DOI: 10.17235/reed.2023.9563/2022

Letter

Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents

DOI: 10.17235/reed.2023.9438/2022

Letter

Henoch-Schönlein purpura masquerading as Crohn’s disease flare

DOI: 10.17235/reed.2022.9414/2022

Original

Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study

DOI: 10.17235/reed.2023.9402/2022

Letter

SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence

DOI: 10.17235/reed.2023.9347/2022

Letter

Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis

DOI: 10.17235/reed.2022.9332/2022

Original

Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.9264/2022

Letter

Use of teduglutide for short bowel syndrome and Crohn’s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy

DOI: 10.17235/reed.2022.9194/2022

Letter

Endoscopic stent placement after spontaneous esophageal perforation associated with chemoradiotherapy for esophageal cancer

DOI: 10.17235/reed.2022.9162/2022

Letter

Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis

DOI: 10.17235/reed.2022.9152/2022

Original

Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

DOI: 10.17235/reed.2022.9101/2022

Review

“Out of the box” new therapeutic strategies for Crohn´s disease: moving beyond biologics

DOI: 10.17235/reed.2022.9010/2022

Letter

The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study

DOI: 10.17235/reed.2022.9006/2022

Letter

A diagnostic challenge: chronic cutaneous ulcers as an isolated clinical finding in metastatic Crohn’s disease

DOI: 10.17235/reed.2022.8995/2022

Digestive Diseases Image

Intestinal and perianal tuberculosis: an uncommon clinical presentation and challenging diagnosis

DOI: 10.17235/reed.2022.8988/2022

Digestive Diseases Image

Peristomal cutaneous Crohn's disease by contiguity

DOI: 10.17235/reed.2022.8909/2022

Review

Efficacy and safety of fecal microbiota transplant for recurrent Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.8814/2022

Letter

One appendix too many: a severe IBD-U case in remission after appendectomy

DOI: 10.17235/reed.2022.8809/2022

Original

Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

DOI: 10.17235/reed.2022.8781/2022

Letter

Combined aortic mural thrombi and limb ischemia in inflammatory bowel disease – A rare vascular manifestation

DOI: 10.17235/reed.2022.8774/2022

Letter

Anal squamous cell carcinoma in HIV patients with HPV-16 condylomas: a serious complication in immunocompromised patients

DOI: 10.17235/reed.2022.8761/2022

Original

Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak

DOI: 10.17235/reed.2022.8668/2022

Original

Anal intraepithelial neoplasia screening in patients with human immunodeficiency virus infection

DOI: 10.17235/reed.2022.8489/2021

Letter

Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

DOI: 10.17235/reed.2021.8397/2021

Review

Diagnostic value of circulating microRNAs for esophageal cancer: a meta-analysis based on Asian data

DOI: 10.17235/reed.2022.8348/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Letter

Ileal endometriosis in a patient with Crohn’s disease: a diagnostic challenge

DOI: 10.17235/reed.2021.8187/2021

Letter

Comparison of satisfaction degree of patients treated at the Inflammatory Bowel Disease Unit (IBDU) of Hospital Universitario 12 de Octubre between previous face-to-face care and telephone care during the COVID-19 pandemic

DOI: 10.17235/reed.2021.8185/2021

Original

Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

DOI: 10.17235/reed.2021.8003/2021

Letter

ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation

DOI: 10.17235/reed.2021.7921/2021

Original

Perianal Crohn’s disease: clinical implications, prognosis and use of resources

DOI: 10.17235/reed.2021.7918/2021

Original

Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes

DOI: 10.17235/reed.2021.7915/2021

Letter

The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move

DOI: 10.17235/reed.2021.7765/2020

Original

Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

DOI: 10.17235/reed.2021.7683/2020

Original

Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

DOI: 10.17235/reed.2021.7638/2020

Letter

Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic

DOI: 10.17235/reed.2020.7562/2020

Original

Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit

DOI: 10.17235/reed.2020.7543/2020

Letter

A case of severe diverticulosis in a patient with ulcerative colitis

DOI: 10.17235/reed.2020.7529/2020

Review

The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease

DOI: 10.17235/reed.2020.7499/2020

Original

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

DOI: 10.17235/reed.2020.7472/2020

Letter

Intestinal obstruction secondary to Crohn-like disease in common variable immu-nodeficiency

DOI: 10.17235/reed.2020.7440/2020

Original

Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center

DOI: 10.17235/reed.2020.7431/2020

Original

Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.7394/2020

Editorial

Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity

DOI: 10.17235/reed.2020.7512/2020

Original

Clinical study of a 125I particle-integrated esophageal covered stent and hyperbaric oxygen in the treatment of advanced esophageal cancer

DOI: 10.17235/reed.2020.7377/2020

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Original

Prognostic value of ultrasound activity and parietal healing in patients with Crohn’s disease

DOI: 10.17235/reed.2020.7347/2020

Original

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response

DOI: 10.17235/reed.2020.7352/2020

Letter

Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept

DOI: 10.17235/reed.2020.7253/2020

Letter

Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease

DOI: 10.17235/reed.2020.7232/2020

Original

Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses

DOI: 10.17235/reed.2020.7230/2020

Original

Ustekinumab treatment for toxic megacolon in severe colonic Crohn’s disease

DOI: 10.17235/reed.2020.7228/2020

Original

Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients

DOI: 10.17235/reed.2020.7202/2020

Review

COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic

DOI: 10.17235/reed.2020.7128/2020

Original

Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn’s disease. A real life study

DOI: 10.17235/reed.2020.7124/2020

Review

Vitamin D and inflammatory bowel disease: what do we know so far?

DOI: 10.17235/reed.2020.7061/2020

Review

The diagnostic and predictive value of fecal calprotectin and capsule endoscopy for small-bowel Crohn’s disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2020.6996/2020

Original

Normalization of long-term quality of life in Crohn’s disease patients receiving ustekinumab

DOI: 10.17235/reed.2020.6941/2020

Original

Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases

DOI: 10.17235/reed.2020.6938/2020

Letter

Gastrointestinal tuberculosis, the great simulator. From inflammatory disease to a tumor

DOI: 10.17235/reed.2020.6934/2020

Letter

Retrograde enteroclysis by double balloon enteroscopy in a patient with blunt abdominal trauma: small bowel stricture, intraluminal vascular lesion and Crohn’s disease

DOI: 10.17235/reed.2020.6891/2020

Original

Treatment of abdominal fistulas in Crohn’s disease and monitoring with abdominal ultrasonography

DOI: 10.17235/reed.2020.6884/2020

Original

Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

DOI: 10.17235/reed.2020.6857/2020

Original

Is endoscopic treatment of small bowel strictures effective and safe in patients with Crohn’s disease?

DOI: 10.17235/reed.2020.6852/2019

Original

Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2020.6851/2019

Original

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

DOI: 10.17235/reed.2020.6847/2019

Letter

Vedolizumab-associated psoriasis: until where does gut selectivity go?

DOI: 10.17235/reed.2020.6817/2019

Original

Is the degree of i2a recurrence in Crohn’s disease secondary to ischemic phenomena?

DOI: 10.17235/reed.2020.6790/2019

Letter

An acute episode of inflammatory bowel disease vs a rare manifestation of an Epstein-Barr virus-positive mucocutaneous ulcer. Case report

DOI: 10.17235/reed.2020.6737/2019

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study

DOI: 10.17235/reed.2020.6693/2019

Original

Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients

DOI: 10.17235/reed.2020.6677/2019

Letter

Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario

DOI: 10.17235/reed.2020.6648/2019

Original

Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit

DOI: 10.17235/reed.2020.6620/2019

Original

Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.6618/2019

Letter

Crohn’s disease in patients treated with etanercept

DOI: 10.17235/reed.2019.6554/2019

Original

Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts

DOI: 10.17235/reed.2020.6552/2019

Original

Lewis score: a useful tool for diagnosis and prognosis in Crohn’s disease

DOI: 10.17235/reed.2020.6434/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Letter

PEG use in patients with squamous cell carcinoma

DOI: 10.17235/reed.2019.6381/2019

Original

Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives

DOI: 10.17235/reed.2019.6310/2019

Original

Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.6298/2019

Case Report

Regression of a giant pseudopolyp in a patient with colonic Crohn’s disease after therapy with infliximab

DOI: 10.17235/reed.2019.6252/2019

Original

Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2019.6148/2018

Letter

Primary squamous cell carcinoma of the stomach: a rare case report

DOI: 10.17235/reed.2019.6121/2018

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Original

The main determinants of disability in IBD and its relationship to optimism

DOI: 10.17235/reed.2019.6033/2018

Original

Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors

DOI: 10.17235/reed.2019.6029/2018

Letter

A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn’s disease

DOI: 10.17235/reed.2019.5990/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Letter

Primary squamous cell carcinoma of the stomach: a rare entity

DOI: 10.17235/reed.2018.5900/2018

Letter

Intravenous ustekinumab reinduction as a Crohn’s disease rescue strategy following a secondary non-response

DOI: 10.17235/reed.2019.5802/2018

Original

The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

DOI: 10.17235/reed.2019.5797/2018

Letter

Crohn’s disease and cystic fibrosis: there is still a lot to learn

DOI: 10.17235/reed.2018.5725/2018

Original

Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity

DOI: 10.17235/reed.2018.5714/2018

Original

Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn’s disease

DOI: 10.17235/reed.2018.5691/2018

Letter

Why anal cytology is not enough in a dysplasia screening program

DOI: 10.17235/reed.2018.5678/2018

Letter

Sweet syndrome after treatment with vedolizumab in a patient with Crohn’s disease

DOI: 10.17235/reed.2018.5603/2018

Original

Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.5600/2018

Original

The association between de novo inflammatory bowel disease and celiac disease

DOI: 10.17235/reed.2019.5535/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Original

A meta-analysis of dietary carbohydrate intake and inflammatory bowel disease risk: evidence from 15 epidemiology studies

DOI: 10.17235/reed.2018.5490/2018

Letter to the Editor

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease

DOI: 10.17235/reed.2018.5456/2018

Original

Bile acid malabsorption in patients with chronic diarrhea and Crohn’s disease

DOI: 10.17235/reed.2018.5376/2017

Original

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOI: 10.17235/reed.2018.5368/2017

Original

Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the “Gestiona hierro-EII” survey

DOI: 10.17235/reed.2018.5354/2017

Original

Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information

DOI: 10.17235/reed.2018.5331/2017

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Review

Intestinal tuberculosis and Crohn’s disease: the importance and difficulty of a differential diagnosis

DOI: 10.17235/reed.2018.5184/2017

Original

Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index

DOI: 10.17235/reed.2017.5137/2017

Original

Can we rely on inflammatory biomarkers for the diagnosis and monitoring Crohn’s disease activity?

DOI: 10.17235/reed.2017.5126/2017

Original

Enteral nutrition is associated with a decreased risk of surgical intervention in Crohn’s disease patients with spontaneous intra-abdominal abscess

DOI: 10.17235/reed.2017.5116/2017

Editorial

The complexity of evaluating and increasing adherence in inflammatory bowel disease

DOI: 10.17235/reed.2017.5143/2017

Original

Capsule endoscopy with PillCamSB2 versus PillCamSB3: has the improvement in technology resulted in a step forward?

DOI: 10.17235/reed.2017.5071/2017

Case Report

Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

DOI: 10.17235/reed.2017.5068/2017

Letter to the Editor

Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

DOI: 10.17235/reed.2017.4941/2017

Original

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn’s disease

DOI: 10.17235/reed.2017.4931/2017

Original

Anal cytology, histopathology and anoscopy in an anal dysplasia screening program: is anal cytology enough?

DOI: 10.17235/reed.2017.4913/2017

Original

Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease

DOI: 10.17235/reed.2017.4845/2017

Case Report

Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease

DOI: 10.17235/reed.2017.4819/2016

Original

Epidemiology of inflammatory bowel disease in Málaga: incidence rate and follow-up of a cohort diagnosed between 2007-2008

DOI: 10.17235/reed.2017.4708/2016

Original

The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire

DOI: 10.17235/reed.2017.4621/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Letter to the Editor

Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis

DOI: 10.17235/reed.2017.4564/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Original

Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab

DOI: 10.17235/reed.2016.4600/2016

Original

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis

DOI: 10.17235/reed.2016.4470/2016

Original

Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease

DOI: 10.17235/reed.2016.4447/2016

Original

Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization

DOI: 10.17235/reed.2016.4440/2016

Original

How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey

DOI: 10.17235/reed.2016.4410/2016

Original

Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease

DOI: 10.17235/reed.2016.4318/2016

Letter to the Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Original

Preliminary results of a screening program for anal cancer and its precursors for HIV-infected men who have sex with men in Vigo-Spain

DOI: 10.17235/reed.2017.4274/2016

Letter to the Editor

Pharmaceutical costs for inflammatory bowel disease units — An issue for department heads? The GESTIONAEII survey

DOI: 10.17235/reed.2016.4192/2016

Case Report

Primary squamous cell carcinoma of the rectum: an atypical histology

DOI: 10.17235/reed.2016.3975/2015

Original

Predictive factors of small bowel patency in Crohn's disease patients

DOI: 10.17235/reed.2015.3957/2015

Original

Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease

DOI: 10.17235/reed.2015.3954/2015

Case Report

Metastatic Crohn’s disease in pediatrics

DOI: 10.17235/reed.2016.3948/2015

Letter to the Editor

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

DOI: 10.17235/reed.2015.3978/2015

Case Report

Immmunodeficiencies and autoimmune diseases: common variable immunodeficiency and Crohn-like

DOI: 10.17235/reed.2015.3872/2015

Letter to the Editor

Crohn’s disease and Sweet’s syndrome: A debut together

DOI: 10.17235/reed.2015.3842/2015

Original

Impact of endoscopic monitoring in postoperative Crohn’s disease patients already receiving pharmacological prevention of recurrence

DOI: 10.17235/reed.2015.3836/2015

Case Report

Primary squamous cell carcinoma of the stomach presenting as a huge retroperitoneal tumor: a case report

DOI: 10.17235/reed.2015.3795/2015

Case Report

Primary liposarcoma of the sigmoid presenting as colonic intussusception - A case report

DOI: 10.17235/reed.2016.3943/2015

Review

Anal Intraepithelial neoplasia: A narrative review

DOI: 10.17235/reed.2015.3788/2015

Case Report

Ovarian involvement in Crohn´s disease: A rare complication

DOI: 10.17235/reed.2015.3764/2015

Citation tools
Quera R, Núñez P, Contreras L, López F, Flores L. Anal neoplasia and perianal Crohn’s disease: myth or reality?. 8317/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 645 visits.
This article has been downloaded 175 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 31/08/2021

Accepted: 09/09/2021

Online First: 24/09/2021

Published: 07/02/2022

Article revision time: 3 days

Article Online First time: 24 days

Article editing time: 160 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology